Ingenia Therapeutics files FDA IND for IGT-303 CKD trial
The Phase 1/2a trial in the U.S. will enroll 94 participants across five sites and assess safety, tolerability and pharmacokinetics.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.